GLTO תחזית צמיחת רווחים לשנה הבאה galecto.com
Galecto, Inc. (GLTO) is developing unique galectin inhibitors to combat cancer and fibrosis, leveraging its patent protection. Shifting analyst estimates for EPS growth visualize this process, with the parameter value reaching -11.90. Future prospects depend on the efficacy of metabolic drugs and strategic partnerships. The company is currently restructuring its pipeline and workforce following unsuccessful tests while maintaining a sufficient liquidity cushion.
GLTO (galecto.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים
Galecto, Inc. (GLTO) development of unique selective galectin inhibitors to combat fibrosis defines the trajectory of the consensus EPS n+1 forecast chart, which currently stands at -11.90. This indicator measures the weighted average analyst expectation for earnings per share changes, where a steady upward curve confirms the company's strong pricing power in an inelastic market and market confidence in the future monetization of its drugs.
